'Gene therapy is at an inflection point': Kathy High on her new perch at AskBio and the field's future
Kathy High needed some time off.
It had been six frenzied years since she co-founded Spark Therapeutics, 15 since she first pitched her Children’s Hospital of Philadelphia colleague Jean Bennett on starting a trial for what would eventually become the first approved gene therapy in the United States. When Roche finally closed their $4.3 billion buyout of Spark last February, High quietly exited for a sabbatical at Rockefeller University in Manhattan.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.